Results 211 to 220 of about 4,410,863 (269)
Trust, but Verify: Translating Dosing Evidence to Understudied Populations in Low- and Middle-Income Countries. [PDF]
Clin Pharmacol Thervan Rensburg R +2 more
europepmc +1 more source
CRISPR/Cas diagnostics for <i>Klebsiella pneumoniae</i>: from resistance and hypervirulence markers to clinically interpretable risk reporting. [PDF]
Front Bioeng BiotechnolYi W +7 more
europepmc +1 more source
Autopsy findings in Alzheimer's disease clinical trial participants demonstrate a high frequency of off-target coexisting pathologic features. [PDF]
J Prev Alzheimers DisCoskun EP +7 more
europepmc +1 more source
Aptamer-Based Heterobifunctional Targeted Degraders in Disease Treatment. [PDF]
MoleculesLiang X +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Strategies for targeting undruggable targets
Expert Opinion on Drug Discovery, 2021Undruggable targets refer to clinically meaningful therapeutic targets that are 'difficult to drug' or 'yet to be drugged' via traditional approaches. Featuring characteristics of lacking defined ligand-binding pockets, non-catalytic protein-protein interaction functional modes and less-investigated 3D structures, these undruggable targets have been ...
Gong, Zhang +4 more
openaire +2 more sources
Circulation Research, 2012
The intriguing biology of microRNAs, small regulatory noncoding RNA molecules encoded by the genome that coordinately regulate gene expression by targeting messenger RNAs, has opened new territories for our understanding of gene regulatory circuits in cardiac homeostasis and disease.
Paula A, Da Costa Martins +1 more
openaire +2 more sources
The intriguing biology of microRNAs, small regulatory noncoding RNA molecules encoded by the genome that coordinately regulate gene expression by targeting messenger RNAs, has opened new territories for our understanding of gene regulatory circuits in cardiac homeostasis and disease.
Paula A, Da Costa Martins +1 more
openaire +2 more sources
Immunotherapy, 2010
745 ISSN 1750-743X Immunotherapy (2010) 2(6), 745–748 10.2217/IMT.10.66 © 2010 Future Medicine Ltd “Although it would be naive to conclude that biomarker programs are cheap and straightforward, it is likely to be a price worth paying in order to maximize the chance of success in the tortuous process of cancer drug development, and, ultimately, to ...
William, Shingler, Richard, Harrop
openaire +2 more sources
745 ISSN 1750-743X Immunotherapy (2010) 2(6), 745–748 10.2217/IMT.10.66 © 2010 Future Medicine Ltd “Although it would be naive to conclude that biomarker programs are cheap and straightforward, it is likely to be a price worth paying in order to maximize the chance of success in the tortuous process of cancer drug development, and, ultimately, to ...
William, Shingler, Richard, Harrop
openaire +2 more sources